In an era increasingly shaped by artificial intelligence, the promise of rapidly scalable, AI-driven enterprises has captivated the global imagination. This vision was notably articulated by OpenAI CEO Sam Altman in 2024, who predicted that a single entrepreneur leveraging AI could generate a business worth over one billion dollars. Matthew Gallagher, a Los Angeles-based entrepreneur, positioned his telehealth startup, MEDVi, as a pioneering fulfillment of this prophecy. Initially heralded by a prominent New York Times profile, MEDVi, which markets GLP-1s and other pharmaceuticals, boasted unprecedented growth, with Gallagher claiming it was "the fastest growing company in history"—a phrase he has since removed from his LinkedIn profile. The Times article, published on April 2, 2026, presented MEDVi as a compelling case study of Altman’s foresight, detailing Gallagher’s AI-powered strategy to achieve a projected $1.8 billion in 2026 sales with a lean operation comprising only two full-time employees—Gallagher himself and his brother Elliot—supplemented by contract engineers, account managers, and external agencies. The Times reported that it was granted access to MEDVi’s financial records to corroborate these impressive revenue and profit figures.
Gallagher attributed MEDVi’s rapid ascent to a suite of AI services, including ChatGPT, Claude, Grok, MidJourney, and Runway, which he utilized for various aspects of the company’s development. For core medical operations—encompassing doctors, pharmacies, shipping, and regulatory compliance—MEDVi reportedly outsourced these functions to telehealth-in-a-box platforms, specifically CareValidate and OpenLoop Health. However, the glowing narrative quickly unraveled as a series of investigations and regulatory actions brought to light a troubling pattern of alleged misbranding, deceptive advertising practices involving AI-generated personas, and significant legal challenges, casting a long shadow over MEDVi’s proclaimed success and the ethical boundaries of AI in healthcare.
The FDA’s Intervention: A Warning on Misbranding
Barely six weeks before The New York Times’ laudatory piece, on February 20, 2026, the U.S. Food and Drug Administration (FDA) issued a stern warning letter to MEDVi. The letter explicitly cited the company for misbranding the compounded drugs that constituted the bulk of its revenue. According to the FDA, MEDVi’s website falsely suggested that the company itself was the compounder of the semaglutide and tirzepatide it sold. More critically, the agency highlighted claims such as "Same active ingredient as Wegovy® and Ozempic®" and "Same active ingredient as Mounjaro® and Zepbound®," asserting that these statements misleadingly implied FDA approval or evaluation of MEDVi’s compounded products. The FDA underscored the gravity of these violations, warning that failure to rectify them could result in severe enforcement actions, including product seizure or injunction. The warning letter also cautioned that the enumerated violations were not an exhaustive list, implying potential for further regulatory scrutiny.
MEDVi, in an April 8 statement, attempted to deflect the FDA’s accusations, claiming that the FDA-cited website, medvi.io, belonged to an affiliate marketing agency and that MEDVi itself had "never received a letter from the FDA." This assertion, however, directly contradicted the FDA’s official warning letter, which was explicitly addressed to "MEDVi, LLC dba MEDVi" at its registered Delaware address, utilized MEDVi’s corporate email address, and specifically referenced MEDVi-branded claims found on medvi.io. This discrepancy immediately raised questions about the company’s transparency and accountability.
A Web of Deception: AI-Generated Personas and Misleading Advertising
Beyond the FDA’s focus on misbranding, independent journalistic investigations uncovered a broader and more pervasive pattern of potentially deceptive marketing. A review by Drug Discovery & Development on April 3, 2026, of MEDVi’s website, Facebook advertising, and public records, revealed a landscape populated by apparent AI-generated personas, some of which were presented with medical titles. The investigation found over 5,000 active ads for "medvi" in Meta’s Ad Library, many operating under what appeared to be fabricated physician identities.
For instance, a Facebook page for "Dr. Robert Whitworth," which sponsored ads for MEDVi’s QUAD erectile dysfunction product, was incongruously categorized as an "Entertainment website" and listed a non-existent address in Cameron, Montana. Other ads featured absurd names like "Professor Albust Dongledore" and "Dr. Richard Hörzgock," utilizing AI-generated video testimonials that recycled identical scripts across multiple fabricated personas. In several instances, a doctor’s headshot would be displayed on the page, while the accompanying ad featured an entirely unrelated individual delivering a patient testimonial. By April 6, a subsequent review indicated that many of these questionable doctor personas had been removed from the site, suggesting a swift, albeit reactive, attempt to address the mounting criticism.
Further corroboration came from a Business Insider investigation published on the same day, which scrutinized the historical use of similar AI-generated doctor profiles in Meta ads for MEDVi, often linked to its affiliates. Matthew Gallagher informed Business Insider that "maybe 30%" of MEDVi’s advertising was conducted through affiliates. Business Insider identified profiles such as "Dr. Matthew Anderson MD" (connected to an Angolan phone number and previously associated with a gospel musician) and "Dr. Spencer Langford MD" (linked to a clothing store in the Republic of Congo), alongside others exhibiting tell-tale signs of AI generation, including garbled text and Gemini watermarks. Following Business Insider‘s inquiries to Gallagher, the number of active Medvi-related ads notably decreased from over 5,000 to approximately 2,800.
Gallagher’s response to Business Insider was that MEDVi adhered to FTC guidelines, maintaining "a clear policy of providing disclosure on any actor or AI portrayal of a doctor or not using them at all." He added, "If we find an affiliate doing this we work to take these ads down." However, this statement appeared to contradict his earlier social media activity, where he equated the use of AI-generated physician personas with standard medical stock art, publicly mocking critics for failing to understand "marketing." Nancy Glick, Director of Food, Nutrition, and Obesity at the National Consumers League, voiced strong criticism of MEDVi, reiterating her organization’s prior warnings against unregulated GLP-1 products.
MEDVi’s own website footer contained a disclaimer acknowledging this practice, stating: "Individuals appearing in advertisements may be actors or AI portraying doctors and are not licensed medical professionals." This fine print, however, was often buried and did not mitigate the initial deceptive impression created by the ads themselves. These findings echo a May 2025 exposé by Futurism, which documented MEDVi’s use of AI-generated patient photos, deepfaked before-and-after weight loss images (traced to photos circulated online for years with faces swapped by AI), and AI-generated Ozempic box imagery containing clear errors. At that time, MEDVi’s site also prominently displayed logos from The New York Times, Bloomberg, and Forbes, implying editorial coverage that had not yet occurred. When Futurism contacted doctors listed on MEDVi’s site, at least one, osteopathic practitioner Tzvi Doron, denied any association with the company and requested his removal. In The New York Times profile, Gallagher later admitted that MEDVi’s initial site indeed featured AI-generated photos and deepfaked weight loss images.
Further scrutiny revealed issues with the medical professionals listed on MEDVi’s site. It previously featured Dr. Ana Lisa Carr and Dr. Kelly Tenbrink, both associated with Ringside Health, a concierge practice in Wellington, Florida, serving the equestrian community. MEDVi’s site did not disclose their affiliation with Ringside Health. While Dr. Tenbrink was listed under the American Board of Emergency Medicine with a verified credential page, his Florida Department of Health practitioner profile stated that he held no specialty board certifications recognized by the Florida board. Similarly, Dr. Carr was listed under her medical school, St. George’s University School of Medicine, with her Florida profile also indicating no recognized specialty board certifications. After Drug Discovery & Development requested comment from both physicians, MEDVi removed them entirely from its website on April 10, 2026.
The Compounding Conundrum: Navigating Regulatory Gaps
MEDVi’s business model hinges on exploiting a nuanced and often contentious regulatory landscape surrounding compounded drugs. Federal law generally prohibits compounding pharmacies from creating copies of FDA-approved drugs. However, Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act permit compounding under specific circumstances, most notably during official drug shortages. The FDA had officially declared the shortage of tirzepatide injection resolved on December 19, 2024, and the semaglutide injection shortage resolved on February 21, 2025.
Following the resolution of these shortages, many sellers, including those in the telehealth space, pivoted to offering "personalized" compounded formulations, frequently adding ingredients like vitamin B-12. They argued that these additions made the compounded product sufficiently distinct from the FDA-approved versions, thus not qualifying as "essentially a copy." However, the FDA countered this interpretation on April 1, 2026, clarifying that a compounded product combining semaglutide with another active ingredient, such as vitamin B-12, could still be considered "essentially a copy" unless a prescriber could document a patient-specific "significant difference" warranting the unique formulation. Pharmaceutical giant Eli Lilly, the manufacturer of tirzepatide (Mounjaro/Zepbound), had already issued a strong warning in March 2026 against the practice of compounding tirzepatide with vitamin B-12, citing safety and efficacy concerns. This regulatory tightening directly impacted MEDVi’s core product offerings and claims.
Mounting Legal Challenges: Data Breaches and "Snake Oil" Allegations
MEDVi’s rapid growth—claiming 250,000 customers by the end of 2025 (as reported by The Times, with Gallagher describing the growth as "insane") and subsequently updating its homepage to "500,000+ MEDVi patients"—has been accompanied by a surge of legal troubles for its partners and, by extension, itself. MEDVi’s platform, which promises "unlimited 24/7 support" and "doctor-led plans & coaching," relies heavily on third-party telehealth infrastructure providers like OpenLoop Health.
OpenLoop Health, a Des Moines, Iowa-based telehealth infrastructure company, disclosed a significant cyber breach on January 7, 2026. A threat actor reportedly infiltrated OpenLoop’s systems, claiming to have exfiltrated records from approximately 1.6 million patients, including sensitive data such as names, contact information, dates of birth, and medical information. OpenLoop notified the Texas Attorney General in March 2026, confirming at least 68,160 affected individuals in that state alone. This breach has led to multiple class-action lawsuits against OpenLoop Health, highlighting critical vulnerabilities in the digital health ecosystem.
Compounding these issues, in November 2025, a North Carolina consumer filed a class-action complaint in the U.S. District Court for the District of Delaware against OpenLoop Health and compounding pharmacy Triad Rx. This lawsuit, first reported by Fierce Healthcare, alleges that the firms manufactured and sold what the complaint provocatively characterized as "modern-day snake oil": compounded oral tirzepatide tablets with "no demonstrated mechanism of absorption or efficacy." While MEDVi was not named as a direct defendant, the complaint explicitly states that the plaintiff purchased these pills through MEDVi, describing it as one of dozens of consumer-facing telehealth storefronts operating within a network managed by OpenLoop.
The lawsuit meticulously detailed the scientific basis for its allegations: tirzepatide, as a large peptide molecule, is inherently susceptible to degradation by digestive enzymes before it can effectively reach the bloodstream. The only FDA-approved oral GLP-1, Rybelsus, necessitates a specialized absorption enhancer called SNAC to achieve even a meager 1% bioavailability, and even then, requires strict administration conditions. The complaint brought claims under the Racketeer Influenced and Corrupt Organizations Act (RICO), state consumer protection statutes, and common law fraud, alleging that MEDVi was part of a larger scheme involving "at least a dozen nearly identical telehealth storefronts," each with a designated OpenLoop patient waiting room, all marketing the same questionable product through shared backend infrastructure.
Furthermore, MEDVi itself has been embroiled in direct legal actions. The company was served in Siuksta v. MEDVi, LLC, a federal Telephone Consumer Protection Act (TCPA) lawsuit filed in May 2025, but failed to appear, leading to a default judgment that was later voluntarily dismissed. Separately, James v. Medvi LLC, a class-action case filed in federal court in California on March 20, 2026, accuses MEDVi of benefiting from affiliate spam. The lawsuit cites an email with the subject line "This might be the easiest way to start Ozempic" sent from a nonsensical email address, routing to a MEDVi landing page with tracking parameters. Filed under California’s anti-spam law, the suit alleges statutory damages of $1,000 per violating email, claiming a class of at least 100,000 individuals.
CEO’s Defense and Public Scrutiny
In the wake of The New York Times profile and the subsequent negative feedback, Matthew Gallagher took to social media to defend MEDVi. In one now-deleted X post, he dismissed detractors as having "low testosterone," labeling them the "Karens of the internet." In another exchange, he directly confronted Shutterstock founder Jon Oringer, who had sarcastically proposed a "fake-doctor affiliate-as-a-service platform." Gallagher equated MEDVi’s use of AI-generated physician personas with standard medical stock art, stating, "The guy who SELLS images of doctors to marketers pretends not to understand marketing. The irony is beautiful," accompanied by a screenshot of a generic stock doctor image. This stance appeared to contradict MEDVi’s April 8 statement, which claimed the company had "recently become aware" of ads featuring "potentially AI-generated medical practitioners," suggesting a lack of candor regarding the extent of their knowledge and involvement.
On April 3, 2026, Gallagher posted a more comprehensive defense of the "white-label telemedicine model" on social media: "Watching in realtime as people learn about white label, drop shipping, and affiliate marketing is like seeing cavemen ‘fire bad.’ White label telemedicine is a huge benefit with a net positive for humanity. It has been the driving force behind big pharma lowering prices and making healthcare accessible to everyone from home. Low energy people think offering life-changing weight loss medication, prescribed by a doctor, is a trendy ‘pill mill.’ Wait til you see what’s possible with longevity services and peptides. I’m bullish on humanity. If you are too, I’ll help you build."
While some on LinkedIn congratulated Gallagher on his AI-first execution and expressed support for his philanthropic goals, others raised significant questions. An SEO professional noted that MEDVi’s reported traffic appeared insufficient to support its claimed user base and revenue figures. A digital health founder remarked, "Something doesn’t add up," while an accountant recommended an independent audit. A viral YouTube video titled "billion dollar ai company was built on lies" garnered over a million views within three days, further fueling public skepticism. Several purported customers also posted direct complaints on LinkedIn, alleging issues with MEDVi’s services.
Drug Discovery & Development reached out to MEDVi, Matthew Gallagher, OpenLoop Health, Dr. Kelly Tenbrink, and Dr. Ana Lisa Carr for comment but did not receive an immediate response. Nicholas Chimicles, lead counsel for the plaintiffs in the class-action lawsuit against OpenLoop and Triad Rx, declined to comment further on the litigation but confirmed his firm’s awareness of The New York Times profile of MEDVi.
Broader Implications for AI, Telehealth, and Pharmaceutical Marketing
The MEDVi saga serves as a critical case study at the volatile intersection of artificial intelligence, telehealth innovation, and pharmaceutical marketing. It underscores the immense potential of AI to accelerate business growth and streamline operations, yet simultaneously highlights the profound ethical and regulatory challenges that arise when such powerful tools are deployed without adequate oversight or a commitment to transparency.
The widespread use of AI-generated personas and deceptive advertising practices raises serious questions about consumer trust in digital healthcare platforms. When medical advice appears to come from non-existent doctors or actors disguised as professionals, the foundational doctor-patient relationship is fundamentally undermined. This erosion of trust can have far-reaching consequences, not only for individual companies but for the entire telehealth industry, which relies heavily on credibility and patient confidence. Regulatory bodies, including the FDA and FTC, face the daunting task of adapting existing frameworks to address the rapid evolution of AI-driven marketing and service delivery. The coalition of 35 attorneys general who wrote to Meta in December 2025, alleging the company’s complicity in permitting deceptive, AI-generated weight-loss ads, exemplifies the growing concern among state and federal regulators. Their statement, "The use of artificial intelligence to fabricate images, spokespeople, and medical claims crosses a line and makes these ads particularly dangerous," encapsulates the urgency of the issue.
Furthermore, the controversy surrounding compounded GLP-1s illuminates the persistent regulatory gap that allows certain products to be marketed without the rigorous safety and efficacy testing mandated for FDA-approved drugs. While compounding serves a vital role in patient care for specific needs, its expansion into mass-marketed alternatives to popular brand-name drugs, especially with questionable added ingredients or delivery mechanisms (like oral tirzepatide without proven absorption enhancers), poses significant public health risks. The FDA’s recent clarifications and Eli Lilly’s warnings are crucial steps, but enforcement remains a complex challenge in a decentralized digital landscape.
Finally, the incident casts a spotlight on the due diligence responsibilities of prominent media outlets. While The New York Times’ initial profile celebrated innovation, the subsequent revelations by Drug Discovery & Development, Business Insider, and Futurism demonstrated the critical role of investigative journalism in scrutinizing even seemingly successful ventures. The MEDVi case underscores that in the age of AI-fueled hype, a deeper, more skeptical look is often necessary to distinguish genuine breakthroughs from potentially deceptive practices. As AI continues to reshape industries, the balance between fostering innovation and safeguarding consumer welfare and public health will remain a paramount concern for regulators, journalists, and the public alike.
Leave a Reply